Table 1.

Xenografts used for the assessment of the tumor-targeting potential of [O-methyl-¹¹C]PD153035.

Cell Line	Disease	Tissue	EGFR Status [41]	Other Mutations [41]	Maximum Uptake (Determined By)
SH-SY5Y	Neuroblastoma	Bone marrow	Wild-type EGFR	ALK	0.23–0.33%ID/mL at 8 min * (PET) [36]
MDA-MB-231	Adenocarcinoma	Mammary gland/breast; pleural effusion	Wild-type EGFR	CDKN2A, BRAF, KRAS, TERT, TP53	0.54 ± 0.10%ID/g at 10 min (ex vivo), T/M 0.84 [38]
MDA-MB-468	Adenocarcinoma	Mammary gland/breast; pleural effusion	Wild-type EGFR (amplification)	PTEN, RB1, TP53	1.39 ± 0.28%ID/g at 10 min (ex vivo), T/M 1.81 [38]
A549	Carcinoma	Lung	Wild-type EGFR	KRAS, STK11, TP53	0.89 ± 0.13%ID/g at 10 min (ex vivo), T/M 1.32 [38] Unknown (PET) [42]
HCC827	Adenocarcinoma	Lung	Del19	TP53	Unknown (PET) [42]
H1975	Adenocarcinoma; NSCLC	Lung	L858R/T790M	PIK3CA, TP53	Unknown (PET) [42]
A431	Epidermoid carcinoma	Skin/epidermis	EGFR-PPARGC1A fusion	TP53	0.3%ID/g at 2–3 min (PET) [37]
PC9	Adenocarcinoma	Lung	Del19	TP53	Unknown (PET) [42]

* Approximate value from the data presented in [36].